Peter Mohr, MD
Ipilimumab (Yervoy) has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.
Ipilimumab is approved in more than 50 countries for the treatment of patients with unresectable or metastatic melanoma.
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma. Bristol-Myers Squibb. Published online and accessed January 22, 2018. http://bit.ly/2DVq5K5.
... to read the full story